CAS: 98769-84-7; Reboxetine Mesylate

该化合物是一种选择性的肾上腺素再摄入抑制剂(NRI),主要用于治疗主要抑制性紊乱症,其中子盐形式可以提高溶性性和生物利用率,确保药物动力性能的一致.该化合物表现出对新肾上腺素运输器(NET)的高度选择性,最大限度地减少与其他单胺系统的互动,有助于形成有利的副作用剖面. Reboxetine meylate的特点是其稳定的晶体结构,有利于精确的配制和制造一致性.其行动机制促进增加合成性肾上腺素水平,支持改善临床环境中的情绪和认知功能.该产品符合严格的药典标准,确保研究和治疗应用的可靠性.

结构式图片

欧盟法规

C&L通报

合成工艺路线路线简述

    海关参考信息

    专利信息


    专利号:US-2011040105-A1
    优先权日:2008-04-16
    标题 :Processes useful for the synthesis of (r)-1--2-methyl-pyrrolidine
    发明人:HUBER CHRISTIAN H; KHULMAN YOUNG MI; TANDEL SAGUN K; JOHANNSEN STEPHEN R; WANG TINGMIN; ANGELL PAUL
    权利人:ARENA PHARM INC
    摘要:Processes useful for making a pharmaceutically useful compound according to Formula (I), forms of such a compound, and intermediates useful in such processes are described.

    专利号:US-7547436-B2
    优先权日:1995-01-17
    标 题:Receptor specific transepithelial transport of therapeutics
    发明人:BLUMBERG RICHARD S; LENCER WAYNE I; SIMISTER NEIL E
    权利人:BRIGHAM & WOMENS HOSPITAL; UNIV BRANDEIS
    摘要:The present invention relates in general to methods and products for initiating an immune response against an antigen, and in particular relates to transepithelial delivery of antigens to provoke tolerance and immunity. The present invention further relates to methods and products for the transepithelial delivery of therapeutics. In particular, the invention relates to methods and compositions for the delivery of therapeutics conjugated to a FcRn binding partner to intestinal epithelium, mucosal epithelium and epithelium of the lung. The present invention further relates to the synthesis, preparation and use of the FcRn binding partner conjugates as, or in, pharmaceutical compositions for oral systemic delivery of drugs and vaccines.

    专利号:US-9751877-B2
    优先权日:2012-09-21
    标题 :Substituted pyrido[1,2-a]pyrazines for the treatment of neurodegenerative and neurological disorders
    发明人:PETTERSSON MARTIN YOUNGJIN; JOHNSON DOUGLAS SCOTT; SUBRAMANYAM CHAKRAPANI; O'DONNELL CHRISTOPHER JOHN; AM ENDE CHRISTOPHER WILLIAM; GREEN MICHAEL ERIC; PATEL NANDINI CHATURBHAI; STIFF CORY MICHAEL; TRAN TUAN PHONG; KAUFFMAN GREGORY WAYNE; STEPAN ANTONIA FRIEDERIKE; VERHOEST PATRICK ROBERT
    权利人:PFIZER
    摘要:Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I n nas defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

    专利号:US-8945508-B2
    优先权日:2009-10-13
    标 题 :Dendrimer compositions and methods of synthesis
    发明人:BAKER JR JAMES R; HUANG BAOHUA
    权利人:BAKER JR JAMES R; HUANG BAOHUA; UNIV MICHIGAN
    摘要:The present invention relates to novel dendrimer compounds and methods of synthesizing the same. In particular, the present invention is directed to novel polyamidoamine (PAMAM) dendrimers, novel dendrimer branching units, methods for synthesizing such novel PAMAM dendrimers and functionalized dendrimers, as well as systems and methods utilizing the dendrimers (e.g., in diagnostic and/or therapeutic settings (e.g., for the delivery of therapeutics, imaging, and/or targeting agents (e.g., in disease diagnosis and/or therapy, etc.))).

    专利号:CN-102066319-A
    优先权日:2008-04-16
    标 题 :Processes useful for the synthesis of (R)-1-{2-[4'-(3-methoxypropane-1-sulfonyl)-biphenyl-4-yl]-ethyl}-2-methyl-pyrrolidine

    专利号:EP-2282992-A1
    优先权日:2008-04-16
    标 题 :Processes useful for the synthesis of (r)-1-{2-ý4'-(3-methoxypropane-1-sulfonyl)-biphenyl-4-yl¨-ethyl}-2-methyl-pyrrolidine
    台州市科瑞生物技术有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.pharm-intermediates.com
    企业联系电话:0576-88813233👤
    📞台州市科瑞生物技术有限公司 ⚠️参考联系方式
    联系人:金崇光
    电话:0576-88813233
    手机:13396860566
    传真:0576-88813233
    邮箱:sales@pharm-intermediates.com
    通信地址: 台州市开发大道东段288号
    邮编: 318000
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    地址:台州市开发大道东段288号
    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
    ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    第 1 / 1 页

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献

    Wośko S, Serefko A, Szopa A, Kardaś S, Widelski J, Mroczek T, Rostkowska E, Szymańska J, Poleszak E. Influence of Smallanthus sonchifolius (Yacon) on the Activity of Antidepressant Drugs in Mice. Life (Basel). 2021 Oct 21;11(11):1117. doi: 10.3390/life11111117. Sołek P, Mytych J, Tabęcka-Łonczyńska A, Koziorowski M. Molecular Consequences of Depression Treatment: A Potential In Vitro Mechanism for Antidepressants-Induced Reprotoxic Side Effects. Int J Mol Sci. 2021 Nov 1;22(21):11855. doi: 10.3390/ijms222111855.
    1: Mergui J, Jaworowski S. Risperidone-Induced Nocturnal Enuresis Successfully Treated With Reboxetine. Clin Neuropharmacol. 2016 Mar 17. [Epub ahead of print] doi: 10.1016/j.pbb.2016.02.005. Epub 2016 Feb 15. doi: 10.1038/npp.2015.194. Epub 2015 Jul 1. doi: 10.1089/cap.2015.0199. Epub 2016 Jan 27. doi: 10.1016/j.pbb.2015.10.006. Epub 2015 Oct 9. doi: 10.1016/j.pharep.2015.04.016. Epub 2015 May 9. doi: 10.1136/bmj.h5842. doi: 10.1177/1550059414532443. Epub 2014 Sep 24. doi: 10.18097/PBMC20156105657. Russian. pii: pyv080. doi: 10.1093/ijnp/pyv080.
    11: Ghanizadeh A. A systematic review of reboxetine for treating patients with attention deficit hyperactivity disorder. Nord J Psychiatry. 2015 May;69(4):241-8. doi: 10.3109/08039488.2014.972975. Epub 2014 Nov 21. Review. doi: 10.1038/nsmb.3029. Epub 2015 May 11.
    13: Yucel A, Yucel N, Ozcan H, Gulec M, Aydin A. Fluoxetine associated with thrombocytopenia and treatment with reboxetine: 3 cases. J Clin Psychopharmacol. 2015 Jun;35(3):354-5. doi: 10.1097/JCP.0000000000000301. doi: 10.1016/j.bbr.2014.12.023. Epub 2014 Dec 16. doi: 10.1097/01.j.pain.0000460313.73358.31. doi: 10.1002/jnr.23473. Epub 2014 Aug 21. doi: 10.1017/S0033291714000221. Epub 2014 Mar 3.

    合成参考文献


    参考文献:10.2165/11530130-000000000-00000
    摘要:Hasnain M, Vieweg WV, Fredrickson SK. Metformin for atypical antipsychotic-induced weight gain and glucose metabolism dysregulation: review of the literature and clinical suggestions. CNS Drugs. 2010 Mar;24(3):193–206. doi: 10.2165/11530130-000000000-00000.
    参考文献:10.1007/s11940-011-0137-6
    摘要:Hirai N, Nishino S. Recent advances in the treatment of narcolepsy. Curr Treat Options Neurol. 2011 Oct;13(5):437–57. doi: 10.1007/s11940-011-0137-6.
    参考文献:10.2165/11592040-000000000-00000
    摘要:Cheung BM. Drug treatment for obesity in the post-sibutramine era. Drug Saf. 2011 Aug 01;34(8):641–50. doi: 10.2165/11592040-000000000-00000.
    参考文献:10.1007/s00213-011-2413-2
    摘要:Wing VC, Shoaib M. Translating the smoking cessation properties of the antidepressant nortriptyline using reinforcing, discriminative and aversive stimulus effects of nicotine in rats. Psychopharmacology (Berl). 2012 Feb;219(3):847–57. doi: 10.1007/s00213-011-2413-2.
    参考文献:10.1007/s10549-005-9056-0
    摘要:Chien C, Li CI, Heckbert SR, Malone KE, Boudreau DM, Daling JR. Antidepressant use and breast cancer risk. Breast Cancer Research and Treatment. 2005 Dec 02;95(2):131–40. doi: 10.1007/s10549-005-9056-0.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知